New Insights into the Nature of the 5q- Deletion Syndrome Based on Quantitative Measurement of BAALC- Expressing Stem Cell Burdens
DOI:
https://doi.org/10.12974/2312-5411.2023.10.02Keywords:
5q- deletion, BAALC-expressing stem cells burdens, Myelodysplastic syndrome, RibosomopathyAbstract
A discovery of nonrandom recurrent interstitial aberration at the long arm of chromosome 5 was made by Van den Berghe et al. in 1974. For a long time, this entity was classified as myelodysplastic syndrome (MDS). Meanwhile, its definition as well as classification criteria were repeatedly changed due to both clinical studies and advances in new techniques. In particular an insufficiency of ribosome-forming protein (RPS14) gene was found soon after similar gene RPS19 discovery in patients with severe inherited Diamond-Blackfan anemia (DBA). It cannot be excluded that basic pathogenetic mechanisms, including participation of activated gene TP53, seem to be similar in both entities.
This article for the first time presents the quantitative data on the BAALC expression in the majority (25/31) of patients tested with 5q- deletions to be under the cut-off values. It concerns a group of 14/16 patients with isolated 5q- anomaly, and 11 other cases in whom 5q- deletion was combined with additional non-identical chromosomal aberrations. On the contrary, this molecular parameter exceeded the cut-off levels in all (n=10) MDS patients without 5q- abnormality. Hence, these data might effectively support an assumption of a ribosomopathy in cases of isolated 5q- deletion. Since about 8-10 % of these patients are transformed into MDS and/or secondary AML, a possible exclusion of isolated 5q- deletion syndrome from MDS category should be discussed carefully and this assumption is needed an additional support in larger studies.
References
Van den Berghe JH, Cassima JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no.5 chromosome. Nature 1974; 251(5474): 437-438. https://doi.org/10.1038/251437a0
Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, Drechsler M et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer 2007; 46: 1119-1128. https://doi.org/10.1002/gcc.20498
Cazzola M. Myelodysplastic syndrome with isolated 5q deletion (5q-syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. Haematologica 2008; 93(7): 967-972. https://doi.org/10.3324/haematol.13377
Barlow JL, Drynan LF, Trim NL, Erber WN, Warren AJ, & McKenzie ANJ. New insights into 5q- syndrome as a ribosomopathy. Cell Cycle 2010; 9(21): 4286-4293. https://doi.org/10.4161/cc.9.21.13742
Pellagatti A, Marafioti T, Paterson JC, Barlow JL, Drynan LF, Giagounidis A, et al. Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood 2010; 115: 2721-2723. https://doi.org/10.1182/blood-2009-12-259705
Narla A, Ebert B. Ribosomopathies: human disorders of ribosome dysfunction. Blood 2010; 115(16): 3196-3205. https://doi.org/10.1182/blood-2009-10-178129
Pellagatti A, Hellstrӧm-Landberg E, Giagomidis A, Perry J, Malocovatti L, Della Porta MG, et al. Haploinsufficiency of RPS14 in 5q- Syndrome is associated with Deregulation of Ribosomal- and Translation-Related Genes. Br. J. Haematol. 2008; 142(0): 57-64. https://doi.org/10.1111/j.1365-2141.2008.07178.x
Starcynowski DT, Kuchenbauer F, Argiropoulus B, Sung S, Morin R, Muranyi A, et al. Identification of MiR-145 and MiR-146a as Mediators of the 5q- Syndrome Phenotype. Nat. Med. 2010; 16(0): 49-58. https://doi.org/10.1038/nm.2054
Pellagatti A, Boultwood J. Recent Advances in the 5q- Syndrome. Mediterr. J. Hematol. Infect. Dis. 2015; 7(1): e2015037. https://doi.org/10.4084/mjhid.2015.037
Yang Z, Keel SB, Shimamura A, Liu L, Gerds AT., Li HY., et al. Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome. Sci. Translat. Medicine. 2016; 8(338): 338 338ra67. https://doi.org/10.1126/scitranslmed.aaf3006
Lee, J-h., List, A., Sallman D.A. Molecular pathogenesis of Myelodysplastic syndrome with deletion 5q. Eur. J. Haematol. 2019; 102: 203-209. https://doi.org/10.1111/ejh.13207
Acha P, Mallo M, Sole F. Myelodysplastic Syndromes with isolated del(5q):Value of Molecular Alterations for Diagnostic and Prognostic Assessment, Cancers (Basel) 2022; 14(22): 5531. https://doi.org/10.3390/cancers14225531
Mamaev NN, Latypova MV, Shakirova AI, Gindina TL, Kanunnikov MM, Tsvetkov NYu, et al. The Role of BAALC-Expressing Leukemia Precursor Cells in the Pathogenesis of Myelodysplastic Syndromes. Clin. Oncohematol. 2022; 15(1): 62-68. (In Russ.) https://doi.org/10.21320/2500-2139-2022-15-1-62-68
Mamaev NN, Shakirova AI, Kanunnikov MM. BAALC-Expressing Cells in Acute Leukemia and Myelodysplastic Syndromes: Present and Future. 2022. Generis Publishing. ISBN: 979-8-88676-457-4
Mamaev NN. Shakirova AI, Barkhatov IM, Gudozhnikova YY, Gindina TL, Kanunnikov MM, et al. Crucial Role of BAALC-expressing leukemic precursors in patients with acute myeloid leukemias. Hematology Transfusion International J. 2020; 8(6): 127-131. https://doi.org/10.15406/htij.2020.08.00240